

# New publication that elucidates Attana's technology's potential to predict drug efficacy

The publication "[Improved Predictions of Drug Efficacy](#)" in the June edition of *EuroLab* describes a method for easy visualization of complex molecular interactions. The purpose of this is to increase the understanding of the impact of complex molecular interactions on drug efficacy and thereby be an important tool in the development of new drugs.

The Journal *EuroLab* is an industrial journal and Attana's primary purpose of this publication is to use it as a marketing tool, e.g. by HVD Life Sciences sales staff. The publication is a collaboration between Linnaeus University, Karlstad University and Attana and is part of the development project Quality Control of Biologics, partly financed by the Swedish Knowledge foundation. The project consists of the companies Attana AB, AstraZeneca, Akzo Nobel Pulp and Performance Chemicals AB and Ridgeview Instruments AB and academic groups from Karlstad University, Linnaeus University och Örebro University.

**For more information, please contact:**

Teodor Aastrup, CEO Attana AB  
e-mail: [teodor.aastrup@attana.com](mailto:teodor.aastrup@attana.com)  
tel: + 46 8 674 57 00

The Board of directors for Attana consider that the information in this press release does not affect the share price, but is of general interest for the share holders and hence should be communicated.

Attana was founded in 2002 with the vision of *in-vitro* characterization of molecular interactions mimicking *in-vivo* conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana's products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana's contract research services and our label free cell-based biosensors, please visit [www.attana.com](http://www.attana.com) or contact [sales@attana.com](mailto:sales@attana.com).